Meeting
2020 ASCO Virtual Scientific Program
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
Authors
John D. Powderly II
Carolina BioOncology Institute, Huntersville, NC
John D. Powderly II, Bartosz Chmielowski , Julie R. Brahmer , Sarina Anne Piha-Paul , Samantha Elizabeth Bowyer , Patricia LoRusso , Daniel V.T. Catenacci , Christina Wu , Minal A. Barve , Michael Jon Chisamore , Nicole Nasrah , Dan Johnson , William Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03674567
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3163)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3163
Abstract #
TPS3163
Poster Bd #
227
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: William Ho
Poster
2023 ASCO Annual Meeting
Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.
First Author: Dirk G. Brockstedt
Poster
2024 ASCO Annual Meeting
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.
First Author: Mohamad Adham Salkeni
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe